Fritextsökning
Innehållstyper
-
Svensk-amerikanskt biotech-företag flyttar in i Forskaren
ITB Med etablerar sitt svenska kontor och laboratorium i Hagastaden. Under sommaren 2024 flyttar det biofarmaceutiska företaget in i Forskaren, på en 500 kvadratmeter stor yta.
-
Swedish nanotech crosses the Atlantic
Genovis signs distribution agreement Finnzymes in US.
-
75 million for research schools
Gothenburg University, Karolinska Institutet, Linköping University and Umeå University have received SEK 75 million from the Research Council. The money will be used to build five national clinical research schools. The research schools will receive 15...
-
High hopes for future partnering - the solution for struggling fairs
Business fairs are struggling but the concept of partnering is hotter than ever. By using social media, participants can prepare themselves for the perfect meeting.
-
Re-painting the big pig-ture
Why do tame pigs show such variety in colouring, when their wild relatives are so plain? Swedish researchers know who is to blame. But the big question is why.
-
Patent-tvist i USA:s högsta domstol kan få stor påverkan
Ett ovanligt patentfall som tagit sig hela vägen till USA:s högsta domstol kan få omfattande konsekvenser för läkemedelspriser och medicinutveckling, rapporterar Nature.
-
From planning stage to handshake
"Partnering is an effective tool to get in touch with the decision makers high up in an organization's administration," says Camilla Huse Bondeson at Conlega. A...
-
Go ahead for leg wound study
Tripep starts a phase II-study of their wound healing joint venture project.
-
Lundbeck divests companies
The company sells all shares in one listed company plus divests four small private equity funds, for a three-figured million sum.
-
Future drugs from Amaryllis
A Danish research team has discovered possibolities to extract drugs fro Amaryllis.
-
Parnevik firm in Swiss osteoporosis deal
The golf legend Jesper Parnevik's drug delivery firm EffRx has signed a license agreement with Nycomed for a new drug against osteoporosis.
-
BMAs: Run your own business
After graduation you must decide: be an employee or start your own business. This is not really the situation for BMAs today, but a collaborative project betwee...
-
Partnering offer for scientists and medics
For the first time in the history of Biotech Forum, scientists and medics are invited to join the partnering event. I
-
Stort vetenskapsmöte igång i Life City
-
Meda gets access to Asia
The biotech giant Meda has recently acquires world-wide rights to the cancer breakthrough pain drug Onsolis.
-
Researchers goes to the bottom of the brain
Swedish researchers have recently got new and deeper knowledge about the smallest part of the brain, the granule cells.
-
Almatec Biocore för hygieniska och sterila applikationer
Aseptiska pumpar med FDA, EHEDG, 3-A, USP Class VI, EC 1935 och ATEX godkännanden.
-
Den enes snor blir den andres bot
Snortransplantation – ordet ger rysningar. Nu presenteras en studie där skånska patienter med kronisk tjock snuva, förbättrades efter att ha använt nässprej inn...
-
Danisco first with green emulsifier
A new sustainable emulsifier from Danisco meets the increasing consumer demand for ethically correct consumer goods.
-
Finnish-Dutch engineering cooperation continues
The University of Helsinki and ASM International renew a fice year research agreement on Atomic Layer Deposition.
-
Att bygga vaccinfabrik i Afrika – i rekordfart
av talarna vid eventet New Horizons in Biologics & Bioprocessing.
-
New tools to fight bacteria
Better guidelines for doctors, detailed patient journals, and national monitoring systems are some of the tools needed to combat the increasing problem of antib...
-
Tanklock för dina tankar
I vårt sortiment erbjuder vi ett brett utbud av trycklösa luckor från vår tillverkare Zimmerlin. Luckorna görs i hög kvalité utefter de höga renlighetskrav som ...
-
Vad händer inom bioprocess närmaste fem åren?
New horizons in bioprocessing and biologics är ett tekniskt möte för de insatta, men vi passar på att fråga. Vad händer inom levande läkemedel närmaste fem åren?